BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs to Present at Upcoming Investor Conferences
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
加利福尼亞州里士滿，2024年11月21日（全球新聞通訊）-- BioAge Labs（納斯達克：BIOA）（「BioAge」，「公司」）是一家臨床階段生物製藥公司，專注於通過靶向人類衰老生物學開發代謝疾病的治療產品候選者。今天，公司宣佈將參加以下即將舉行的投資者會議：
- Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a company presentation on December 3, 2024 from 1:30 PM to 1:55 PM EST, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
- Citi 2024 Global Healthcare Conference (Miami, December 3-5, 2024): Kristen Fortney, CEO and co-founder, PhD, is scheduled to participate in a company presentation on December 4, 2024 from 3:15 PM to 3:55 PM EST, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
- 派傑投資第36屆年度醫療保健會議（紐約，2024年12月3日至5日）：首席執行官兼聯合創始人Kristen Fortney博士定於2024年12月3日下午1:30至1:55（東部標準時間）參加公司發佈，並將參加一對一會議。要訪問演示的實時網絡直播，註冊 這裏.
- 花旗2024全球醫療保健會議（邁阿密，2024年12月3日至5日）：首席執行官兼聯合創始人Kristen Fortney博士定於2024年12月4日下午3:15至3:55（東部標準時間）參加公司發佈，並將參加一對一會議。要訪問演示的實時網絡直播，註冊 這裏.
Replays of the webcasts will be available in the investor section of the company's website at , and will be archived for 30 days following the presentations.
網絡講座的重播將在公司網站的投資者部分提供，位於 並將在演示後的30天內歸檔。
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge's lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. In mid-2024, BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge's preclinical programs, based on novel insights from the company's discovery platform built on human longevity data, address key pathways in metabolic aging.
。
BioAge是一家處於臨床階段的生物製藥公司，致力於開發治療代謝性疾病（如肥胖）的候選藥物，通過針對人類衰老生物學。BioAge的首席候選藥物，azelaprag，是APJ的口服小分子激動劑，據觀察在第10億臨床試驗中促進新陳代謝並防止臥牀休息時的肌肉萎縮。2024年中，BioAge啓動了azelaprag與tirzepatide聯合治療老年人肥胖的2期試驗。Azelaprag有潛力作爲口服方案，可在接受促胰島素藥物肥胖療法的患者中增強體重減輕和改善體重分佈。BioAge還在開發口服小分子穿腦NLRP3抑制劑，用於治療由神經炎症驅動的疾病。BioAge的臨床前項目基於公司建立在人類長壽數據上的發現平台的新穎見解，解決了代謝老化中的主要途徑。
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web:
聯繫方式
PR：Chris Patil，media@bioagelabs.com
IR：Elena Liapounova，ir@bioagelabs.com
合作：partnering@bioagelabs.com
網站:
譯文內容由第三人軟體翻譯。
